// App-Quantinova.ai

P3-11-09 : ARISTACAT - Aromatase inhibition plus minus saracatinib as advanced breast cancer therapy: A randomised phase II study of aromatase inhibition plus/minus the Src-inhibitor AZD0530 in post-menopausal women with advanced breast cancer

Researchers

Presenter

  • David Cameron

Principal Investigators

  • Stefan Symeonides

  • Murray Brunt

  • Peter Schmid

  • Simon Waters

  • Christopher Twelves

  • Peter Barrett-Lee

  • John Bartlett

  • Tammy Piper

  • Karen McAdam

  • Eve Macdonald Chisholm

  • Michelle Welsh

  • Robert Hill

Medical Centers

  • University of Edinburgh, Cancer Research UK Edinburgh Centre, Edinburgh, United Kingdom

  • University Hospitals of North Midlands NHS Trust, Stafford, United Kingdom

  • Bart's Cancer Institute, London, United Kingdom

  • Velindre Hospital, Whitchurch, Cardiff, United Kingdom

  • University of Leeds, St Jamess University Hospital, Leeds, United Kingdom

  • Velindre Cancer Centre, Cardiff, United Kingdom

  • University of Edinburgh, Cancer Research Centre & OICR, Toronto, Toronto, ON, Canada

  • Peterborough City Hospital, Peterborough, United Kingdom

  • Scottish Clinical Trials Research Unit, Edinburgh, United Kingdom

Locations

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Aromatase

Drug/Treatment

  • saracatinib

  • AZD-0530

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved